On December 6, 2021 MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, reported that it will be participating in the Lytham Partners Winter 2021 Investor Conference taking place from December 13-16, 2021 (Press release, Mannkind, DEC 6, 2021, View Source [SID1234596492]). During the event, the Company’s Chief Executive Officer, Michael Castagna, PharmD, will be participating in a webcasted Fireside Chat discussing its vision for 2022 and Mr. Castagna and the Company’s Chief Financial Officer, Steven B. Binder will be conducting 1×1 virtual investor meetings.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcasted Fireside Chat will be available for viewing at 11:00 AM ET on Monday, December 13, 2021, on the Company’s website at View Source The webcast will also be archived and available for replay.

To arrange a 1×1 meeting with management, please contact Lytham Partners at 1×[email protected] or register at www.lythampartners.com/winter2021invreg.